In an attempt to bolster its presence in gastrointestinal cancers, GSK has agreed to acquire IDRx for US$1.15 B. Through the takeover, GSK will gain access to IDRx’s lead asset, IDRX-42, which is designed to target gastrointestinal stromal tumours (GIST). IDRX-42 is a highly selective KIT tyrosine kinase inhibitor (TKI) currently being evaluated in a Phase I/IIb trial. Recent data has already shown promising anti-tumor activity of IDRX-42 in GIST patients with a manageable safety profile. IDRX-42 will enhance GSK's existing gastrointestinal cancer portfolio which includes Jemperli (dostarlimab) and the B7-H3-targeted antibody-drug conjugate, GSK5764227.